Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_assertion description "[Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_assertion evidence source_evidence_literature NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_assertion SIO_000772 19387466 NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_assertion wasDerivedFrom befree-2016 NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_assertion wasGeneratedBy ECO_0000203 NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.
- befree-2016 importedOn "2016-02-19" NP734212.RAHxaHiXiuWt8JF4ZW3HkF6O2bVr0H0MkJWD-KU6CVGy0130_provenance.